Non-invasive Brain Stimulation in Children With Autism

Autism Spectrum Disorder Clinical Trial

Official title:

A Pilot Study of Transcranial Direct Current Stimulation (tDCS) in Children With Autism Spectrum Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05105126
• Other study ID #: Pro2020000931
• Status: Recruiting
• Phase: N/A
• Start date: February 1, 2022
• Est. completion date: December 30, 2023

Study information

• Verified date: February 2023
• Source: Rutgers, The State University of New Jersey
• Contact: J. Helen Yoo, Ph.D.
• Phone: (718) 494-5295
• Email: JHelen.Yoo[@]opwdd.ny.gov
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although many children diagnosed with autism spectrum disorder (ASD) make significant progress in learning and their cognitive skills improve with applied behavior analysis (ABA), there are a significant number of children who show an absence or a plateau in various skills. Deficits in executive functioning are likely to be involved in many of these cognitive and learning disabilities due to poor functioning of the prefrontal cortex. Currently, the use of biological methods for improving learning and cognition is largely unexplored in research and practice. The aim of this study is to use of transcranial direct current stimulation (tDCS) in combination with ABA to improve the acquisition of educational programs for students with ASD. tDCS is a low-level electrical neurostimulation and is most effective when used in combination with an active training or teaching, facilitating the neuronal circuits used for that task. tDCS has been used for various indications over a couple of decades and has been shown to be very safe and has been well-tolerated by children with ASD. The mechanism of tDCS is not clear, however animal studies show that tDCS can stimulate the flow of calcium ions through channels in the astrocytes, activating them, and facilitating their role in synapse formation and therefore learning.

Description:

Children with ASD experience a wide range of outcomes, and not all children respond effectively to behavioral interventions. This study uses a novel biologic intervention that combines electrical brain stimulation with ABA treatment to target some of the cognitive deficits in ASD that until now have been relatively refractory to treatment. There is accumulating evidence of tDCS being effective in treating the comorbidities as well as the core symptoms of ASD. tDCS is most effective when used simultaneously with an active intervention. In this study, the effects of tDCS alone and in combination with ABA on the executive functioning skills and the core symptoms of ASD will be examined and monitored using an objective neurophysiological test (EEG). This is a double-blind, sham-controlled crossover study involving 20 participants. tDCS will be administered while ABA therapy is being implemented. Programs aimed at language and other cognitive functions will be emphasized. tDCS will be applied bi-frontally with the anode at F3 and the cathode at F4. Forty stimulation sessions will be done (20 active, 20 sham) lasting 20 minutes per session, at 1 milliampere.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 24
• Est. completion date: December 30, 2023
• Est. primary completion date: June 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 12 Years

Eligibility

Inclusion Criteria:

1. Males and females between 5 and 12 years with autism

2. Enrolled in an ABA program (school or in-home) supervised by a Board Certified Behavior Analyst (BCBA)

3. Stable medical and behavioral treatments for at least 4 weeks prior to, and during the study

4. Able to tolerate wearing tDCS as determined during a week-long daily desensitization training.

Exclusion Criteria:

1. Any implanted metal device (heart pacemaker, cochlear implant, surgical clips, etc.)

2. Severe neurological disorders such as TBI, brain tumor, intracranial infection

3. Seizure disorder with a seizure within the last two years

4. Skull defect

5. Peripheral blindness or deafness

6. Medication that might affect tDCS: There have been a few studies concerning the effect of various medications on tDCS. Some may block and others may enhance the effects depending on many factors. The assay used to test these medications was its effect on the motor cortex after stimulation and this may not apply to our montages, however, in order to minimize the chances of having medication affect our results, participants

taking the following medications will be excluded:

1. Na or Ca channel blockers which will include all anti-seizure medications

2. Medications that affect the NMDA receptors including dextromethorphan, cycloserine

3. Serotonin reuptake inhibitors

4. Dopamine stimulating or blocking medications including pergolide, bromocriptine and all antipsychotic medications

5. Norepinephrine stimulating or blocking agents including propranolol and the stimulants

6. Drugs that can lower seizure threshold [imipramine, amitriptyline, doxepin, nortriptyline, maprotiline, chlorpromazine, clozapine, foscarnet, ganciclovir, ritonavir, amphetamines, phencyclidine, ketamine, gamma-hydroxybutyrate (GHB), alcohol, theophylline]

7. Barbiturates, benzodiazepines, meprobamate, chloral hydrate in the past 4 weeks

7. Acute skin disease

8. History of magnetic or electrical stimulation

Related Conditions & MeSH terms

• Autism Spectrum Disorder
• Autistic Disorder
• Child Autism
• Child Development Disorders, Pervasive
• Executive Dysfunction

Intervention

Device:
• Transcranial Direct Current Stimulation (tDCS)
The anodal electrode will be placed over F3 using the international 10-20 EEG electrode placement system to target the left dorsolateral prefrontal cortex (DLPFC). The cathode electrode will be placed on the right dorsolateral prefrontal cortex. 40 stimulation sessions will be completed (20 active, 20 sham), each lasting 20 minutes per session at 1.0mA.
• Sham tDCS
Sham tDCS

Locations

Country	Name	City	State
United States	Department of Pediatrics, Division of Pediatric Neurology, Robert Wood Johnson Medical School	New Brunswick	New Jersey

Sponsors (3)

Lead Sponsor	Collaborator
Rutgers, The State University of New Jersey	Boston Children's Hospital, New York State Institute for Basic Research

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Vineland Adaptive Behavior Scales (for demographic purposes)	Parent reported daily living skills	Once during baseline
Other	Leiter-3 nonverbal intelligence assessment (for demographic purposes)	Nonverbal intelligence test	Once during baseline (if a similar test was not done in the past three years)
Primary	Change in the Behavior Rating Inventory of Executive Function (BRIEF)	The BRIEF is a parent-reported executive function questionnaire which utilizes T-scores, which has a mean of 50 with a standard deviation of 10, with a range of 10-100	Change measured once per month for 5 months
Primary	Change in Electrodncephalogram (EEG)	Power, sample entropy, Lyapunov exponent, detrended fluctuation analysis, correlation dimension, and recurrence quantitative analysis (RQA) values on all frequency bands (delta, theta, alpha, beta, gamma, and gamma+) will be computed from 2-minute resting EEGs using a portable headset	Change measured once per month for 5 months
Secondary	Change in the Pervasive Developmental Disorder Behavior Inventory (PDDBI)	The PDDBI is a parent-reported questionnaire about the symptoms of ASD. The PDDBI utilizes T-scores, which has a mean of 50 with a standard deviation of 10, with a range of 10-100. The higher the Approach/Withdrawal Problems and the higher the Autism scores, the more severe the deficits. The higher the Receptive/Expressive Social Communication scores, the better the competence in these areas	Change measured once per month for 5 months
Secondary	Change in discrete trial training (DTT) data from applied behavior analysis (ABA) therapy	Individualized behavior data from ABA therapy	Obtained once at the completion of the study (5 months after the start of the study)